Literature DB >> 21339307

The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer.

Gong Yang1, Xue Xiao, Daniel G Rosen, Xi Cheng, Xiaohua Wu, Bin Chang, Guangzhi Liu, Fengxia Xue, Imelda Mercado-Uribe, Paul Chiao, Xiang Du, Jinsong Liu.   

Abstract

PURPOSE: NF-κB is a transcription factor known to promote tumorigenesis. However, NF-κB is also known to be proapoptotic and may potentially function as a tumor suppressor, although such a functional role has not been extensively investigated in human cancer. EXPERIMENTAL
DESIGN: A dominant-negative mutant of IκBα with mutations at S32A and S36A was used to inhibit the function of NF-κB in ovarian cancer cell lines. The transcription ability, tumorigenesis, apoptosis, and drug sensitivity were examined in derivative cell lines in comparison with parental cells. We also analyzed the association of nuclear expression of NF-κB p65 with patient survival in an ovarian cancer tissue array.
RESULTS: We show that NF-κB functions as a tumor suppressor in four ovarian cancer cell lines, but it functions as an oncogene in their aggressive chemoresistant isogenic variants. NF-κB can exert its proapoptotic or antiapoptotic effect by activating or repressing mitogen-activated protein kinase (MAPK) phosphorylation in parental or aggressive chemoresistant variant cell lines. We also show that the nuclear accumulation of p65 in epithelial cancer tissue is associated with a good response to chemotherapy and can predict longer overall survival for patients with ovarian cancer.
CONCLUSIONS: Our data provide strong evidence that NF-κB can function as a biphasic regulator, either suppressing or enhancing ovarian cancer growth through the regulation of MAPK and cellular apoptosis. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21339307      PMCID: PMC3152795          DOI: 10.1158/1078-0432.CCR-10-3265

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

Review 1.  Control of apoptosis by Rel/NF-kappaB transcription factors.

Authors:  M Barkett; T D Gilmore
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

Review 2.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

3.  IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines.

Authors:  Yi Huang; Weimin Fan
Journal:  Mol Pharmacol       Date:  2002-01       Impact factor: 4.436

4.  Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation.

Authors:  J A Brockman; D C Scherer; T A McKinsey; S M Hall; X Qi; W Y Lee; D W Ballard
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

5.  Role of NF-kappaB in p53-mediated programmed cell death.

Authors:  K M Ryan; M K Ernst; N R Rice; K H Vousden
Journal:  Nature       Date:  2000-04-20       Impact factor: 49.962

6.  Identification and characterization of an IkappaB kinase.

Authors:  C H Régnier; H Y Song; X Gao; D V Goeddel; Z Cao; M Rothe
Journal:  Cell       Date:  1997-07-25       Impact factor: 41.582

7.  Active ERK contributes to protein translation by preventing JNK-dependent inhibition of protein phosphatase 1.

Authors:  Martha M Monick; Linda S Powers; Thomas J Gross; Dawn M Flaherty; Christopher W Barrett; Gary W Hunninghake
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

8.  Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma.

Authors:  Lilach Kleinberg; Hiep Phuc Dong; Arild Holth; Björn Risberg; Claes G Trope'; Jahn M Nesland; Vivi Ann Flørenes; Ben Davidson
Journal:  Hum Pathol       Date:  2009-01-20       Impact factor: 3.466

9.  Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis.

Authors:  Lesley A Stark; Malcolm G Dunlop
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

10.  Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Elena Fountzilas; Kamana Pillay; Luiz F Zerbini; Towia A Libermann; Stephen A Cannistra; Dimitrios Spentzos
Journal:  BMC Med Genomics       Date:  2008-11-28       Impact factor: 3.063

View more
  43 in total

1.  Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Abigail D Winder; Kruti P Maniar; Jian-Jun Wei; Dachao Liu; Denise M Scholtens; John R Lurain; Julian C Schink; Barbara M Buttin; Virginia L Filiaci; Heather A Lankes; Nilsa C Ramirez; Kay Park; Meenakshi Singh; Richard W Lieberman; Robert S Mannel; Matthew A Powell; Floor J Backes; Cara A Mathews; Michael L Pearl; Angeles Alvarez Secord; David J Peace; David G Mutch; William T Creasman; J Julie Kim
Journal:  Cancer       Date:  2016-12-07       Impact factor: 6.860

2.  Poor survival with wild-type TP53 ovarian cancer?

Authors:  Kwong-Kwok Wong; Daisy I Izaguirre; Suet-Yan Kwan; Erin R King; Michael T Deavers; Anil K Sood; Samuel C Mok; David M Gershenson
Journal:  Gynecol Oncol       Date:  2013-06-22       Impact factor: 5.482

3.  Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression.

Authors:  Jonathan Stewart; Jacqueline James; Glenn W McCluggage; Stephen McQuaid; Kenneth Arthur; David Boyle; Paul Mullan; Darragh McArt; Benedict Yan; Gareth Irwin; D Paul Harkin; Lei Zhengdeng; Chee-Wee Ong; Jia Yu; David M Virshup; Manuel Salto-Tellez
Journal:  Mod Pathol       Date:  2014-09-26       Impact factor: 7.842

4.  TLR4 activates NF-κB in human ovarian granulosa tumor cells.

Authors:  Dori C Woods; Yvonne A R White; Caroline Dau; A L Johnson
Journal:  Biochem Biophys Res Commun       Date:  2011-05-17       Impact factor: 3.575

5.  Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway.

Authors:  Miriam B F Werneck; Eugênio Hottz; Patricia T Bozza; João P B Viola
Journal:  Cell Cycle       Date:  2012-09-19       Impact factor: 4.534

6.  A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.

Authors:  Xin-Shuai Wang; De-Jiu Kong; Tzu-Yin Lin; Xiao-Cen Li; Yoshihiro Izumiya; Xue-Zhen Ding; Li Zhang; Xiao-Chen Hu; Jun-Qiang Yang; She-Gan Gao; Kit S Lam; Yuan-Pei Li
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

7.  Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells.

Authors:  Lizhou Jia; Shiwu Zhang; Yanfen Ye; Xin Li; Imelda Mercado-Uribe; Robert C Bast; Jinsong Liu
Journal:  Cancer Lett       Date:  2012-08-15       Impact factor: 8.679

8.  Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.

Authors:  S Zhang; I Mercado-Uribe; Z Xing; B Sun; J Kuang; J Liu
Journal:  Oncogene       Date:  2013-03-25       Impact factor: 9.867

Review 9.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

10.  NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells.

Authors:  Carrie D House; Elizabeth Jordan; Lidia Hernandez; Michelle Ozaki; Jana M James; Marianne Kim; Michael J Kruhlak; Eric Batchelor; Fathi Elloumi; Margaret C Cam; Christina M Annunziata
Journal:  Cancer Res       Date:  2017-10-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.